Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy

Fig. 1

ATP1A1 expression in samples from melanoma patients. A Representative IHC of ATP1A1 in melanoma metastases. Examples of staining intensity scored at 0 (−), 1 (+), 2 (+ +) and 3 (+ + +) (scale bars = 50 µm). B Kaplan–Meier curves comparing overall survival between groups with low (blue) and high (red) ATP1A1 protein levels (Cox regression). C ATP1A1 mRNA levels in 8 patient biopsies collected prior targeted therapies and defined as responders (blue) or non-responders (red) to the BRAF inhibitor vemurafenib (Mann–Whitney test). D Evaluation of the correlation between ATP1A1 and a panel of phenotype markers of pigmented versus invasive melanomas, 448 cutaneous melanomas were investigated using the cBioPortal for Cancer Genomics (http://www.cbioportal.org/) based on TCGA, PanCancer Atlas data sets. All correlations are significant (p < 0.001, Spearman rho test)

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us